You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

47 Results
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Archived
ID: 2-20-2
Sep 2005
Guidelines and Advice
Statistical Reports
Statistical Reports
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Jun 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
Jun 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Jun 2025

Pages